Investigational drug · Phase 2
NBIP-01435
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Congenital Adrenal Hyperplasia.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NBIP-01435"
First trial start
2026
Dec 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NBIP-01435", any sponsor or status.
Conditions studied
As listed on its trial records.
- Congenital Adrenal Hyperplasia
Approved drugs for the same conditions: Rare and genetic disease · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "NBIP-01435" as an intervention, largest first.
- Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)Not yet recruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07850739 · 36 participants (planned) · Start Dec 1, 2026 · Primary completion Mar 16, 2028
Drug: NBIP-01435 · For: Congenital Adrenal Hyperplasia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Congenital Adrenal Hyperplasia
- CRN04894AtumelnantPhase 35 trials
Crinetics Pharmaceuticals Inc. · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia, Cushing Syndrome
- Lu AG13909AsedebartPhase 23 trials
H. Lundbeck A/S · Cushing's Disease, Congenital Adrenal Hyperplasia, Adrenal Hyperplasia, Congenital
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Neurocrine Biosciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.